EIDD-2749|1613589-24-4|(4'-FlU; 4'-Fluorouridine)-陌孚医药/Medlife

您当前的位置：

EIDD-2749 (Synonyms: 4'-FlU; 4'-Fluorouridine)

目录号: PL11100 纯度: ≥99%

CAS No. :1613589-24-4

商品编号	规格	价格	会员价
PL11100-5mg	5mg	¥4203.64	请登录
PL11100-10mg	10mg	¥6800.00	请登录
PL11100-25mg	25mg	¥13600.00	请登录
PL11100-50mg	50mg	询价	询价
PL11100-100mg	100mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	EIDD-2749
英文名称	EIDD-2749
英文别名	4'-C-Fluoro-uridine;Uridine, 4'-C-fluoro-;4'-FlU, EIDD-2749;EIDD-2749
Cas No.	1613589-24-4
分子式	C₉H₁₁FN₂O₆
分子量	262.19
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	EIDD-2749 (4'-Fluorouridine) 是一种口服有效的 RdRp 抑制剂。EIDD-2749 能有效抑制 RSV 和 SARS-CoV-2 的复制。EIDD-2749 还表现出抗 HCV 和淋巴细胞性脉络丛脑膜炎病毒 (LCMV) 的活性。EIDD-2749 是一种很有潜力的 COVID-19 口服治疗候选剂，也适用于其他 RNA 病毒的研究。
生物活性	EIDD-2749 (4-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses.
性状	Solid
IC50 & Target[1][2]	RdRp, RSV,SARS-CoV-2, HCV, COVID-19, LCMV.
体外研究(In Vitro)	EIDD-2749 induces a delayed stalling of phosphodiester bond formation by RSV and SARS-CoV-2 RdRP. EIDD-2749 is rapidly anabolizes, metabolically stable, and potently antiviral in disease-relevant well-differentiated HAE cultures. EIDD-2749 shows a ≥17-fold increase in anti-RSV potency relative to that on HEp-2 cells; however, the low cytotoxicity levels remains unchanged (CC50 169 mM), resulting in a high SI (SI = EC50/CC50) of ≥1877. EIDD-2749 inhibits SARS-CoV-2 with an EC50 value of 0.2-0.6 M. EIDD-2749 has an EC50 of 1.86 μM in theVero E6 cell line, cytotoxicity with a CC50 of 380 μM, and stability in human plasma. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	EIDD-2749 (0.2, 1, 5 mg/kg; p.o.; single daily for 4 days) shows good orally efficacious in RSV infection mice model in a dose-dependent manner. EIDD-2749 shows high efficacious to SARS-CoV-2 infection and is effective with a single daily dose versus molnupiravir administered twice daily in vivo. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Sourimant J, et al. 4-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science. 2022 Jan 14;375(6577):161-167. [2]. Abas AH, et al. 4’-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review [version 1; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2022, 11:410.

溶解度数据	In Vitro: H₂O : 62.5 mg/mL (238.38 mM; Need ultrasonic)DMSO : 25 mg/mL (95.35 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation